Article | April 26, 2024

The Relevance Of ePROs In Early Phase Clinical Trials

Source: Kayentis
GettyImages-1389580785 patient tech

Early phase clinical research, encompassing phases 1 and 2a, serves as the cornerstone for understanding the behavior of investigational products in humans and determining optimal dosages and safety profiles. However, the integration of patient perspectives and electronic Patient Reported Outcomes (ePROs) into these phases is increasingly recognized as pivotal for both scientific advancement and market success. By embracing ePROs from the outset, clinical teams gain valuable insights into patient experiences, streamline trial design for later stages, and bolster the overall market value of their innovations.

Here, we delve into how early adoption of ePROs not only refines clinical development strategies but also cultivates a deeper understanding of patient needs, ultimately reshaping the landscape of pharmaceutical innovation and market access.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader